Publication:
Protein kinase D2 modulates hepatic insulin sensitivity in male mice.

Research Projects

Organizational Units

Journal Issue

Abstract

Protein kinase D (PKD) family is emerging as relevant regulator of metabolic homeostasis. However, the precise role of PKD2 in modulating hepatic insulin signaling has not been fully elucidated and it is the aim of this study. PKD inhibition was analyzed for insulin signaling in mouse and human hepatocytes. PKD2 was overexpressed in Huh7 hepatocytes and mouse liver, and insulin responses were evaluated. Mice with hepatocyte-specific PKD2 depletion (PKD2) and PKD2 mice were fed a chow (CHD) or high fat diet (HFD) and glucose homeostasis and lipid metabolism were investigated. PKD2 silencing enhanced insulin signaling in hepatocytes, an effect also found in primary hepatocytes from PKD2 mice. Conversely, a constitutively active PKD2 mutant reduced insulin-stimulated AKT phosphorylation. A more in-depth analysis revealed reduced IRS1 serine phosphorylation under basal conditions and increased IRS1 tyrosine phosphorylation in PKD2 primary hepatocytes upon insulin stimulation and, importantly PKD co-immunoprecipitates with IRS1. In vivo constitutively active PKD2 overexpression resulted in a moderate impairment of glucose homeostasis and reduced insulin signaling in the liver. On the contrary, HFD-fed PKD2 male mice displayed improved glucose and pyruvate tolerance, as well as higher peripheral insulin tolerance and enhanced hepatic insulin signaling compared to control PKD2 mice. Despite of a remodeling of hepatic lipid metabolism in HFD-fed PKD2 mice, similar steatosis grade was found in both genotypes. Results herein have unveiled an unknown role of PKD2 in the control of insulin signaling in the liver at the level of IRS1 and point PKD2 as a therapeutic target for hepatic insulin resistance.

Description

This work was funded by grants PID2023-150994OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to PR; PID2021-122766OB-100 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to AMV; PID2020-115218RB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” to TI; PID2021-124425OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by “ERDF/EU” to PA; PDC2021- 121147-I00 funded by MICIU/AEI/10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR” to GS. We also acknowledge grants PI20/00837 to CG-M, PMP21/00057 to GS and PA, and PI22/01968 to ÁG-R funded by Instituto de Salud Carlos III/FEDER (Spain), and IT1476-22 funded by Basque Government, Department of Education (Spain) to PA, grants P2022/BMD-7227 funded by Comunidad de Madrid (Spain) to AMV and AG and funding from CIBERDEM (ISCIII, Spain) to AMV and CIBERNED (ISCIII, Spain) to TI, including PR and JPU research contracts, respectively. CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033). EC-L is funded by Comunidad de Madrid and Fondo Social Europeo (ref. PEJ2020-AI/BMD-18301).

MeSH Terms

DeCS Terms

Bibliographic citation

Mol Metab. 2024 Dec:90:102045.

Related dataset

Related publication

Document type